NYPOZI
Growthfilgrastim-txid
BLAINJECTIONINJECTABLE
Approved
Jun 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NYPOZI (filgrastim-txid) is colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation, differentiation commitment, and some end-cell functional activation. First approved in 2024.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NYPOZI (filgrastim-txid) is a granulocyte colony-stimulating factor (G-CSF) biosimilar approved in June 2024 for chemotherapy-induced neutropenia (CIN). It works by binding to cell surface receptors on hematopoietic cells to stimulate neutrophil proliferation, differentiation, and functional activation. The drug is indicated for patients experiencing neutropenia as a consequence of chemotherapy.
Growth
Recently approved biosimilar entering a moderately competitive market with established players; expect small, focused commercial team building market access and penetration.
Mechanism of Action
Colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation, differentiation commitment, and some end-cell functional activation. Endogenous G-CSF is a lineage-specific colony-stimulating factor that is…
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NYPOZI offers entry into biosimilar commercialization at a growth-stage product, ideal for professionals focused on payer negotiations, market share capture, and rapid scaling. Roles emphasize access strategy and pricing defense rather than innovative science, suitable for commercially-minded career builders in a competitive, mature segment.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.